Date Title
February 15, 2019
Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting
Highlights - Proposed disposal of hypochlorous acid (HOCl) Assets to Urgo, U.S. Inc., for $10 million (gross) - Proposed adoption of an Investing Policy and delisting of Ordinary Shares from AIM; ADSs to remain listed for trading on Nasdaq - Circular available on the websites of Realm and the U.S.
February 15, 2019
Realm Therapeutics - Update on Strategic Review
RNS Number : 2805Q Realm Therapeutics PLC 15 February 2019     THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY
November 29, 2018
Realm Therapeutics - Update on Strategic Review
RNS Number : 7939I Realm Therapeutics PLC 29 November 2018     THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY
October 1, 2018
Realm Therapeutics - Provides Update on Timing of Formal Sale Process
RNS Number : 4338C Realm Therapeutics PLC 01 October 2018   Realm Therapeutics plc (" Realm Therapeutics ", "Realm" or the "Company")   Provides Update on Timing of Formal Sale Process     MALVERN, PA , October 1, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a biopharmaceutical company
September 17, 2018
Realm Therapeutics - Corporate Update and Hiring of Advisor

RNS Number : 8941A Realm Therapeutics PLC 17 September 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY

August 14, 2018
Realm Therapeutics - Half-year Report

RNS Number : 7159X Realm Therapeutics PLC 14 August 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY

August 8, 2018
Realm Therapeutics - Presents at Wedbush PacGrow Healthcare Conference

RNS Number : 1132X Realm Therapeutics PLC 08 August 2018   Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference     MALVERN, PA , August 8, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel

August 7, 2018
Realm Therapeutics - Notice of Results

RNS Number : 9887W Realm Therapeutics PLC 07 August 2018       Realm Therapeutics to Report First Half 2018 Financial Results     MALVERN, PA , August 7, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in

July 16, 2018
Realm Therapeutics - Holding(s) in Company
RNS Number : 8036U Realm Therapeutics PLC 16 July 2018   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
July 10, 2018
Realm Therapeutics - Pre-Clinical Study in Atopic Dermatitis
RNS Number : 0857U Realm Therapeutics PLC 10 July 2018     Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis     MALVERN, PA , July 10, 2018 - Realm Therapeutics plc (NASDAQ:RLM /
Displaying 1 - 10 of 136

Search Investor Relations